Home News Clinical Trials

Clinical Trials

Dr. Atul NC Peters recognized as ‘International Surgeon of Excellence’ by Surgical Review Corporation...

Patients who have undergone Bariatric surgery walk the ramp in a unique fashion show New Delhi, 29thApril, 2015 :Dr Atul NC Peters, Director, Bariatric, Metabolic and Minimum Access Surgery, Fortis Hospital, Shalimar Bagh was adjudged the...

Clinical Research is a big challenge in current regulatory scenarios in India.

Dr. Devesh Kumar, MD Founder and Managing Director Innovate Research Pvt. Limited     Entering into service industry especially Clinical Research is a big challenge in current regulatory scenarios in India.   Dr. Devesh and team has taken...

Clinical Trial Norms to be more stringent in India

New Delhi January 10, 2014: The Indian government plans to tighten clinical trials regulation in India by focusing on the ethics committees, which are responsible for clearing the clinical trials. It aims at making it mandatory for the ethics...

Sanofi Expands Access to Clinical Trial Data

New Delhi January 10, 2014: The drug company, Sanofi plans to expand access to the data and information related to its clinical trials, which are sponsored by Sanofi group of companies. This initiative aims at promoting the set of...

.MP Baijayant “Jay” Panda Asks India to Embrace Modern Science in Support of Humane...

MP Baijayant "Jay" Panda Asks India to Embrace Modern Science in Support of Humane Society International's Campaign to End Animal Testing for Cosmetics

New Delhi, Delhi, India, Thursday, March 14, 2013 -- (Business Wire India) -- Member of Parliament Baijayant "Jay" Panda calls on the government to end animal testing for cosmetics in India - giving a boost to a campaign that is spreading around the world. Panda, an elected representative from Kendrapara, Odisha, wrote letters to the Ministers of Health and Family Welfare, Environment and Forests, and Consumer Affairs, supporting Humane Society International/India's call to end to cosmetic testing on animals as soon as possible.

Phase III DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival...

Berlin, January 3, 2013 – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase III trial of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement in progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. The safety and tolerability were generally consistent with the known profile of Nexavar. Detailed efficacy and safety analysis from this study are expected to be presented at an upcoming medical meeting. Effective treatment options are urgently needed for patients with RAI-refractory differentiated thyroid cancer,” said Dimitris Voliotis, MD, Vice President, Global Clinical Development Oncology, Bayer HealthCare. “We are pleased that the results of this study demonstrate that Nexavar may provide a treatment option for these patients.